Peripheral Neuropathy Trial, Recruiting NCT07602387 Sponsor: Hospital Ambroise Paré Paris Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT07602387
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, with no upper age limit
  • People who have given their signed agreement to take part in the study
  • People who are members of the French social security system
  • People who are able to attend all appointments for the full length of the study
  • People who can read and understand French
  • People who agree with how the study works and are able to follow its requirements
  • People who have nerve damage in the lower limbs (legs and feet) caused by taxane-based chemotherapy drugs (paclitaxel or docetaxel), lasting at least 3 months, rated as grade 2 to 4 in severity using a standard medical scale (NCI-CTCAE version 5) — a nerve function test (EMG) may be arranged if one has not been done in the past year, though a normal result does not prevent participation
  • People who have ongoing nerve pain in the lower limbs lasting at least 3 months, with a score of 4 or more out of 10 on a neuropathic pain questionnaire (DN4), and pain rated at least 4 out of 10 in intensity
  • People whose pain is located in the lower limbs, where a capsaicin 8% patch can be applied
  • People who are either not taking pain relief medication, or whose pain relief medication has remained unchanged for at least 2 weeks before joining the trial

Who may not be able to join:

  • People who are involved in legal action or seeking financial compensation related to their condition
  • People with metastatic cancer (cancer that has spread to other parts of the body)
  • People with a known cause of nerve damage other than chemotherapy, such as diabetes, a systemic disease, an underactive thyroid, alcohol-related causes, kidney failure, or a genetic condition
  • People with a condition affecting the peripheral or central nervous system, with or without nerve pain
  • People with an uncontrolled ongoing health condition, such as severe obesity, sleep apnea, or uncontrolled high blood pressure
  • People with psychosis, a history of a suicide attempt, or a current major depressive episode
  • People with a history of drug or psychoactive substance misuse
  • People with thinking or psychological difficulties that would make it hard to understand or follow the study requirements
  • People who are currently taking part in another medical research study
  • People for whom the eye examination (confocal corneal microscopy) is not suitable — for example, those who wear contact lenses long-term or who have had eye surgery, laser eye treatment for short-sightedness, or dry eye condition
  • Women who are pregnant or breastfeeding
  • People who are under legal guardianship or protection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Didier BOUHASSIRA, MD, PhD, Institut National de la Santé Et de la Recherche Médicale, France

Phone: 0033149094556

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hospital Ambroise Paré Paris
Registry
ClinicalTrials.gov
Start date
12 March 2024
Est. completion
1 March 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

density of small nerve fibers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov